<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="98953">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01659658</url>
  </required_header>
  <id_info>
    <org_study_id>C16011</org_study_id>
    <secondary_id>2011-005468-10</secondary_id>
    <nct_id>NCT01659658</nct_id>
  </id_info>
  <brief_title>Study of Dexamethasone Plus MLN9708 or Physician's Choice of Treatment in Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis</brief_title>
  <official_title>A Phase 3, Randomized, Controlled, Open-label, Multicenter, Safety and Efficacy Study of Dexamethasone Plus MLN9708 or Physician's Choice of Treatment Administered to Patients With Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Millennium Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Millennium Pharmaceuticals, Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>European Union: European Medicines Agency</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 3, randomized, controlled, open-label, multicenter study of the oral
      formulation of dexamethasone plus MLN9708 compared with treatment chosen by the investigator
      from a prespecified list of regimens available in clinical practice.  Treatment options will
      include: dexamethasone alone, dexamethasone plus an alkylating agent (melphalan or
      cyclophosphamide), or dexamethasone plus an immunomodulatory drug (IMiD, thalidomide or
      lenalidomide) in patients with relapsed or refractory AL amyloidosis. Crossover to the
      investigational treatment arm is not permitted during participation in this study.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Anticipated">August 2018</completion_date>
  <primary_completion_date type="Anticipated">May 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Number of patients with overall hematologic response</measure>
    <time_frame>Assessed every 4 weeks (median length of the endpoint assessment period is projected to be approximately 36 months)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Complete response, very good partial response and partial response</description>
  </primary_outcome>
  <primary_outcome>
    <measure>2-year vital organ deterioration and mortality rate</measure>
    <time_frame>Monthly for up to 2 years or until death</time_frame>
    <safety_issue>No</safety_issue>
    <description>Rate of hospitalization for congestive heart failure or progression to end stage renal disease or death at 2 years</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients with complete hematologic response</measure>
    <time_frame>Assessed every 4 weeks (median length of the endpoint assessment period is projected to be approximately 36 months)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Overall complete hematologic response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Monthly up to 5 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Time from randomization to the date of death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>Monthly up to 5 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Time from date of randomization to the date of first documentation of disease progression or death, whichever occurs first</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hematologic disease progression free survival</measure>
    <time_frame>Monthly up to 5 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Time from the date of randomization to the date of first documented hematologic disease progression or death, whichever occurs first</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to vital organ deterioration and mortality rate</measure>
    <time_frame>Monthly up to 5 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Time from date of randomization to the first date of either death or hospitalization for congestive heart failure or progression to endstage renal disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with cardiac and/or kidney response</measure>
    <time_frame>Every 3 cycles until disease progression</time_frame>
    <safety_issue>No</safety_issue>
    <description>Overall organ response rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital organ progression free survival</measure>
    <time_frame>Every 3 cycles until disease progression</time_frame>
    <safety_issue>No</safety_issue>
    <description>Time from the date of randomization to the date of first documentation of progression of vital organ, or death, whichever occurs first</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of hematologic response</measure>
    <time_frame>Monthly up to 5 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Time from the date of first documentation of hematologic response to the date of first documented hematologic disease progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of adverse events</measure>
    <time_frame>Monthly up to 5 years</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Adverse events, serious adverse events, assessment of clinical laboratory values from the date of signing of the informed consent form through 30 days after the last dose of study drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to treatment failure</measure>
    <time_frame>Monthly up to 5 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Time from date of randomization to the date of first documented treatment failure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to subsequent anticancer treatment</measure>
    <time_frame>Monthly up to 5 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Time from date of randomization to the start date of subsequent anticancer treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Results of Quality of Life Assessment</measure>
    <time_frame>At screening; Cycle 1, Day 1; Cycle 2, Day 1; Cycle 3, Day 1; Day 1 of every 3 cycles until disease progression</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of medical encounters patient experiences</measure>
    <time_frame>At screening; Cycle 1, Day 1; Cycle 2, Day 1; Cycle 3, Day 1; Day 1 of every 3 cycles until disease progression</time_frame>
    <safety_issue>No</safety_issue>
    <description>Number of admissions to an inpatient and outpatient setting for any reason (including length of stay, inpatient, outpatient, reason, number of missing days from work or other activities by patient or care-giver and EQ-5D scores questionnaire data</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to reach plasma concentration</measure>
    <time_frame>Cycle 1, Days 1 and 14; Cycle 2, Days 1 and 14; Cycles 3-10, Day 1</time_frame>
    <safety_issue>No</safety_issue>
    <description>Pharmacokinetics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigate the association of clinical outcomes and polymorphic genes</measure>
    <time_frame>At screening</time_frame>
    <safety_issue>No</safety_issue>
    <description>Analysis of relevant signaling pathway genes in whole blood samples</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">248</enrollment>
  <condition>Relapsed or Refractory Systemic Light Chain Amyloidosis</condition>
  <arm_group>
    <arm_group_label>MLN9708 plus Dexamethasone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive MLN9708 (4.0 mg) orally (PO) on Days 1, 8, and 15 plus dexamethasone 20 mg/day PO weekly on Days 1, 8, 15, and 22 of each 28-day cycle; dexamethasone may be increased up to 40 mg/day after 4 weeks, if tolerated. Patients may continue to receive treatment until PD or unacceptable toxicity, whichever comes first.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Physician's Choice</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive one of the following treatment options as selected by the physician:
Dexamethasone: 20 mg/day orally (PO) on Days 1-4, 9-12 &amp; 17- 20 of each 28-day cycle
Dexamethasone + melphalan: Dexamethasone 20 mg/day PO on Days 1-4 of each 28-day; plus melphalan 0.22 mg/kg PO on Days 1-4 every 28 days.
Dexamethasone + cyclophosphamide: Dexamethasone 20 mg/day PO weekly on Days 1, 8, 15 &amp; 22 of each 28-day cycle; plus cyclophosphamide 500 mg PO Days 1, 8 &amp; 15 every 28 days.
Dexamethasone + thalidomide: Dexamethasone 20 mg/day PO weekly Days 1, 8, 15 &amp; 22 of each 28-day cycle; plus thalidomide total dose up to 200 mg/day PO
Dexamethasone + lenalidomide: Dexamethasone 20 mg/day PO weekly on Days 1, 8, 15 &amp; 22 of each 28-day cycle; plus lenalidomide 15 mg/day for 21 days every 28 days.
In all treatments dexamethasone may be increased up to 40 mg/day after 4 weeks, if the lower dose is tolerated without any &gt; Grade 2 dexamethasone-related toxicities.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MLN9708</intervention_name>
    <arm_group_label>MLN9708 plus Dexamethasone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <arm_group_label>MLN9708 plus Dexamethasone</arm_group_label>
    <arm_group_label>Physician's Choice</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melphalan</intervention_name>
    <arm_group_label>Physician's Choice</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <arm_group_label>Physician's Choice</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thalidomide</intervention_name>
    <arm_group_label>Physician's Choice</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenalidomide</intervention_name>
    <arm_group_label>Physician's Choice</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female patients 18 years or older

          -  Biopsy-proven AL amyloidosis with relapsed or refractory disease despite 1 or 2 prior
             therapies.  Patients may be proteasome inhibitor-exposed or naive, but cannot be
             refractory to proteasome inhibitor therapy

          -  Disease requiring further treatment

          -  Measurable disease as defined by serum differential free light chain concentration
             (dFLC)

          -  Objective and measurable major organ involvement (ie, cardiac or renal) as defined by
             the standard International Society of Amyloidosis (ISA) criteria.

          -  Eastern Cooperative Oncology Group (ECOG) performance status of less than or equal to
             2

          -  Meet the clinical laboratories criteria as specified in the protocol

          -  Female patients who are post menopausal, surgically sterile, or agree to practice 2
             effective methods of contraception through 90 days after the last dose of study
             treatment or agree to practice true abstinence; must also adhere to the guidelines of
             any treatment specific pregnancy prevention program

          -  Male patients who agree to practice effective barrier contraception through 90 days
             after the last dose of study treatment or agree to practice true abstinence AND must
             adhere to the guidelines of any treatment specific pregnancy prevention program

          -  Voluntary written consent

        Exclusion Criteria:

          -  Amyloidosis due to mutations of the transthyretin gene or presence of other non-AL
             amyloidosis

          -  Female patients who are lactating, breastfeeding or pregnant

          -  Evidence of current uncontrolled cardiovascular conditions as specified in study
             protocol

          -  Clinically overt multiple myeloma as specified in study protocol

          -  Inability to swallow medication, inability or unwillingness to comply with the drug
             administration requirements, or gastrointestinal (GI) procedure that could interfere
             with the oral absorption or tolerance of treatment

          -  Requirement for other concomitant chemotherapy, immunotherapy, radiotherapy, or any
             ancillary therapy considered to be investigational or which would be considered as a
             treatment of AL amyloidosis. However, patients may be on chronic steroids (maximum
             dose 20 mg/day prednisone or equivalent if they are being given for disorders other
             than amyloidosis

          -  Comorbid systemic illnesses or other severe concurrent disease which, in the judgment
             of the investigator, would make the patient inappropriate for entry into this study
             or interfere significantly with the proper assessment of safety and toxicity of the
             prescribed regimens

          -  Ongoing or active infection, known HIV positive, active hepatitis B or C infection

          -  Psychiatric illness/social situations that would limit compliance with study
             requirements

          -  Known allergy to any of the study medications, their analogues or excipients

          -  Systemic treatment with strong inhibitors of CYP1A2, strong inhibitors of CYP3A, or
             strong CYP3A inducers, or use of Ginkgo biloba or St. John's wort within 14 days
             before the first dose of study treatment

          -  Diagnosed or treated for another malignancy within 5 years before study enrollment or
             previously diagnosed with another malignancy and have any evidence of residual
             disease. Patients with nonmelanoma skin cancer or carcinoma in situ of any type are
             not excluded if they have undergone complete resection
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Millennium Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>For an updated listing of recruitment sites contact: Millennium Medical and Drug Information Center</last_name>
    <phone>1-877-674-3784</phone>
    <email>medical@mlnm.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mayo Clinic Arizona</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85359</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Reeder</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048-18</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lill</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Cleveland Clinic</name>
      <address>
        <city>Weston</city>
        <state>Florida</state>
        <zip>33331</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>IU Simon Cancer Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Boston Medical Center HEM/ONCO</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tufts Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Barbara Ann Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dispenzieri</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10017</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heather Landau</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Abramson Cancer Center of Univ of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Goodman</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Froedtert &amp; Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Princess Alexandra Hospital</name>
      <address>
        <city>Woolloongabba</city>
        <state>Queensland</state>
        <zip>QLD 4102</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal Prince Alfred Hospital</name>
      <address>
        <city>Camperdown, NSW</city>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joshua</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sir Charles Gairdner Hospital</name>
      <address>
        <city>Nedlands</city>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Westmead Hospital</name>
      <address>
        <city>Westmead, NSW</city>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kwok</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tom Baker Cancer Centre</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4N2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kukreti</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vancouver General Hospital</name>
      <address>
        <city>Vancouver</city>
        <zip>V5Z1M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Århus University Hospital</name>
      <address>
        <city>Aarhus</city>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Niels Andersen</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Limoges</name>
      <address>
        <city>Limoges</city>
        <state>Cedex</state>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jaccard</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Huriez, CHRU</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leleu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Hotel-Dieu Nantes</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe Moreau</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Saint Louis</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fermand</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Rangueil</name>
      <address>
        <city>Toulouse Cedex 09</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dominique Chauveau</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Charité Universitätsmedizin Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>12200</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital, Amyloidosis Center Med.</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>General Hospital of Athens</name>
      <address>
        <city>Athens</city>
        <zip>11528</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kastritis</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University General Hospital of Patras</name>
      <address>
        <city>Patras</city>
        <zip>26500</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Symeonidis</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hadassah Medical Center - Hadassah University Hosp</name>
      <address>
        <city>Jerusalem</city>
        <zip>91120</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gatt</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Meir Medical Center</name>
      <address>
        <city>Kfar Saba</city>
        <zip>44281</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hardan</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rabin Medical Center, Beilinson Hospital</name>
      <address>
        <city>Petah-Tiqva</city>
        <zip>49100</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ofer Shpilberg</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Policlinico S. Orsola-Malpighi</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cavo</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro Amiloidosi Padiglione Forlanini - 3° Piano</name>
      <address>
        <city>Pavia</city>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Gachon University Gil Medical Center</name>
      <address>
        <city>Incheon</city>
        <zip>405-760</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lee</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>SungSoo Yoon</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seoul St Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chang Ki Min</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>KiHyun Kim</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>VUMC Ams VUMC Amsterdam</name>
      <address>
        <city>Amsterdam</city>
        <zip>1018 HV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Groningen Unit for Amyloidosis Research &amp; Develop.</name>
      <address>
        <city>Groningen</city>
        <zip>9731 GZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vellenga</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Maastricht University Medical Centre</name>
      <address>
        <city>Maastricht</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gerard Bos</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>UMC Utrecht</name>
      <address>
        <city>Utrecht</city>
        <zip>3508</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Minnema</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic I Provincial</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Blade</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de la Princesa</name>
      <address>
        <city>Madrid</city>
        <zip>2800</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alegre</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of Salamanca</name>
      <address>
        <city>Salamanca</city>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mateos</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oxford University Hospitals NHS Trust</name>
      <address>
        <city>Oxford</city>
        <state>Oxon</state>
        <zip>OX3 7LE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ramasamy</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University College London Medica School</name>
      <address>
        <city>London</city>
        <zip>NW3 2PF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wechalekar</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Australia</country>
    <country>Canada</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <lastchanged_date>September 13, 2013</lastchanged_date>
  <firstreceived_date>August 2, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>MLN9708</keyword>
  <keyword>Amyloidosis</keyword>
  <keyword>Light Chain</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Amyloidosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Thalidomide</mesh_term>
    <mesh_term>Lenalidomide</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone 21-phosphate</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
